Impact Factor 2.889 | CiteScore 3.1

More on impact ›

Review ARTICLE

Front. Neurol., 22 December 2020 | https://doi.org/10.3389/fneur.2020.565665

Acute Ischemic Stroke in SARS-CoV, MERS-CoV, SARS-CoV-2: Neurorehabilitation Implications of Inflammation Induced Immunological Responses Affecting Vascular Systems

  • 1School of Psychology and Public Health, La Trobe University, Melbourne, VIC, Australia
  • 2Faculty of Social and Political Sciences, Ivane Javakhishvili Tbilisi State University, Tbilisi, Georgia
  • 3Department of Neurology, Australian Institute for Musculoskeletal Science, Level Three, Western Centre for Health Research and Education, Sunshine Hospital, Western Health & University Melbourne, St Albans, VIC, Australia
  • 4Department of Medicine, Faculty of Medicine, University of Rajarata, Anuradhapura, Sri Lanka

Coronaviruses (CoVs) are enveloped RNA viruses and have been shown to cause mild to severe respiratory infections in humans, with some severe cases inducing neurological manifestations. The lethality and Neurological effects of the Severe Acute Respiratory Syndrome (SARS-CoV), Middle-East Respiratory Syndrome (MERS-CoV), and recently the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) have been well documented though currently there is little literature regarding long term effects and the implications for neurorehabilitation. SARS-CoV-2 and MERS-CoV have been linked to the infection associated inflammatory cytokine storms and induced hypercoagulopathic states that affect the entire vascular system including that of the brain. This mini-review provides an overview of the commonalities among studies published on all three types of the coronavirus related to acute ischemic stroke (AIS). The aim was to elucidate the physiological mechanisms underpinning COVID-2 and to reflect the similarities with the chronic inflammation induced symptoms of AIS that are likely to prove a further challenge for neurorehabilitation clinicians post COVID. In terms of increased incidence of COVID and AIS, it is likely that in depth knowledge of increased thrombotic risk in this population will require appropriate anticoagulation treatment, and other therapeutic interventions as well as neurorehabilitation interventions. Lastly the risk of spreading the virus requires further balancing of the provision of neurorehabiliatation services useful to the patient.

Introduction

Currently, four genera of Coronavirina have been identified, three of which can infect mammals (1). Alpha and beta coronaviruses include the Severe acute respiratory syndrome (SARS-CoV), Middle East respiratory syndrome (MERS-CoV), and Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants (2, 3). Extensive research in the last two decades has traced the evolutionary origins of these organisms to warm-blooded flying vertebrates where they are non-pathogenic (4). Indeed, a molecular epidemiological study conducted by Woo et al. in 2012 suggests that bats are the most likely sources of coronaviruses and that bats have been instrumental in its widespread dissemination and evolution since 8100 BC (5). The primary entry point of the coronavirus family is the angiotensin-converting enzyme 2 (ACE2) receptor which is ubiquitous across human tissues, especially on epithelial and endothelial cell surfaces. ACE2 plays a vital role in the transmission of the virus as the targeted receptor of the SARS-CoV-2, virus, especially on the epithelia of the respiratory system. Impairment of normal functioning of the ACE2 receptors following the invasion of the virus leads to down regulation of the Renin Angiotensin Aldosterone system (RAAS) and cascade of inflammatory events culminating in pneumonia, severe acute respiratory distress syndrome, multi-organ failure and has led to numerous fatalities during earlier regional outbreaks in China (SARS-CoV), Saudi Arabia (MERS-CoV), and globally SARS-CoV-2 (6). The presence of the ACE2 receptor in other tissues such as the gut, cardiac muscles, and the glial cells of the nervous system contributes to its myriad of manifestations (79). Neurological manifestations of coronaviruses were first described during the SARS CoV epidemic in 2002 (10). Tsai et al. reported cases of neuropathies, myopathies, and strokes during the SARS I epidemic while encephalitis and acute inflammatory demyelinating polyneuropathy (AIDP), and Gullian-Barre syndrome (GBS) have also been described in patients with MERS-CoV by Kim et al. (10, 11). Currently, during the SARS-CoV-2 pandemic, an increasing number of patients have presented with stroke and other neurovascular complications as well as the aforementioned manifestations (9, 12).

The following research questions guided this mini review:

a. What is the incidence of stroke among patients with SARS, MERS, and SARS-CoV-2?

b. What are the main pathophysiological mechanisms of acute ischemic stroke in patients with SARS, MERS, and SARS-CoV-2?

c. What are the potential/best treatment options for best clinical outcomes of stroke patients with SARS, MERS, and SARS-CoV-2?

d. What is the balance between treating patients while maintaining the case management tailored to avoid the diffusion of infection?

Methods

Search Strategy

The concepts of this mini review included studies reporting on the incidence, treatment options, and challenges of ischemic stroke patients with confirmed SARS, MERS, and SARS-CoV-2 infection.

The following search strategy was followed (13):

1. In the first step MEDLINE, Cochrane, and CINAHL databases were searched, followed by title and abstract search.

2. In the second step, the keywords were used when searching on Ovid MEDLINE, Cochrane, PubMed, CINAHL, and EMBASE databases.

3. In the last step, a manual search was carried out to ensure no study was inadvertently left out.

The keywords used to conduct the search were: Stroke, thrombosis, coronavirus, neurorehabilitation, neurological complication, SARS-CoV, MERS-CoV, coronavirus, COVID19, SARS-CoV-2, and autopsy.

Study Methodologies

Most of the studies included were case reports and case series. Six of the publications were retrospective cohorts while the rest were systematic reviews and commentaries; See Table 1 for key papers.

TABLE 1
www.frontiersin.org

Table 1. Summary of studies on acute ischemic stroke patients with human SARS, MERS, SARS2 (13).

Results

The Incidence of Stroke With SARS, MERS, and SARS-COV2

The occurrence of stroke in patients with coronavirus infection was first detailed by Umapathi et al. in four out of the 206 patients with SARS infection in Singapore in 2002. All patients presented with large vessel occlusion (14). Two patients with ischemic stroke (IS) and intracerebral hemorrhage (ICH) were also described in MERS-CoV-infected patients in Saudi Arabia during the 2002 epidemic (15, 17). Most recently, there has been growing concerns about the occurrence of stroke, predominantly affecting large vessels, among confirmed SARS-CoV-2 cases (25). The World Stroke Organization (WSO) has recently identified that stroke increases the severity of SARS-CoV-2 infection by 2.5-fold (21, 41).

While much of the focus has been on cardiovascular, pulmonary, and hematologic complication, there has been a corresponding increase in morbidity and mortality due to neurological complications. According to Bridwell et al. (42), these include acute cerebrovascular events, encephalitis, Guillain-Barré syndrome, acute necrotizing hemorrhagic encephalopathy, and hemophagocytic lymphohistiocytosis (42). Pre-existing neurological conditions have also been linked to more severe COVID-19 infections. It has been documented that elderly patients with chronic medical conditions who contract COVID-19 can present with acute encephalopathy and altered level of consciousness (43).

According to level 1 evidence, “remdesivir therapy in mild to severe disease, and the triple medication regimen (lopinavir-ritonavir, ribavirin, and interferon beta-1b) in mild to moderate disease are promising agents against SARS-CoV-2 in terms of symptom improvement and time to a negative RT-PCR, while further studies are needed (25). However, many of the recently proposed medications, such as antivirals and antimalarials have significant drug interactions and side effects, especially with patients with prior strokes (42). It is important that medical staff are cognizant of potential neurological complications when treating COVID-19. Because some of the neurological manifestations tend to occur early in the illness, neurologists, and neurorehabilitation teams need to be involved, alert, and prepared during the pandemic period (44).

A literature review of neurological manifestations and complications of COVID-19 suggests that most commonly reported symptoms include headache, dizziness, hypogeusia, and neuralgia, followed by stroke, seizures, encephalopathy, and delirium (45, 46). It also highlights that some of the neurological manifestations can precede the typical manifestations such as fever, cough, sore throat, and headaches. The neurological damage caused by COVID-19 can be divided into central and peripheral effects and is likely due to hypoxic brain injury and immune mediated damage to the central nervous system. Currently, the proportion of patients with neurological manifestations is much smaller compared to those with respiratory disease. However, as the pandemic progresses, it is expected that the overall number of patients with neurological symptoms will increase. Neurological complications such as stroke and encephalitis can cause lifelong disability, resulting in long term care needs, associated rehabilitation needs and large health, social and long-term care needs and large health, social, and economic costs (47).

While the incidence of stroke among hospitalized patients with Covid-19 is relatively low, patients in their 30s, 40s, and 50s diagnosed with COVID-19 have presented with large-vessel occlusion stroke (25). Social distancing and isolation are important preventive measures; however, patients with acute neurological symptoms delaying calling an ambulance because of concerns about going to a hospital during the pandemic may contribute to poor outcomes. While strokes occurring in younger, asymptomatic patients with COVID-19 are concerning, patients not seeking care for symptoms of stroke are equally worrying. The overall incidence is low; however, the prognosis of acute ischemic stroke among young adults with COVID-19 is grim. There is evidence that young asymptomatic people are developing clots that cause major stroke. In a small sample, the mortality rate among the COVID-19 patients was 42.8%; the typical mortality from stroke varies between 5 and 10% (45).

Three cases of stroke were also reported during the MERS-CoV epidemic affecting more than 2,500 patients globally so far (48). Majority of the patients were males (66%) older than 45 years (66%). Only one patient was younger than 45 (33%). The average age was 54 years old. The majority had a previous history of HPN (66%), and all suffered from DM (100%). Only one (33%) had a prior history of stroke. All three patients died.

In the most recent SARS-CoV2 pandemic, stroke has been one of the main vascular complications documented. Of the total SARS-CoV2 patients identified in the reported studies, number of males and females are quite comparable; A quarter younger than 45 years, and around half older than 65.

In a university hospital in Italy, among 388 symptomatic and laboratory-confirmed SARS-CoV-2 patients, eight (2%) were diagnosed (after testing positive for COVID) to have ischemic stroke (18). Klok et al. also recorded the occurrence of ischemic stroke in 1.6% (3/188) of all SARS-CoV-2 pneumonia patients admitted in the intensive care unit (ICU) Netherland (19). Neurologic manifestations were also reported in 214 cases in Wuhan, China and among these, five (2.3%) patients presented with ischemic stroke (9). Conversely, Meza et al. reviewed 354 ischemic stroke patients admitted in a local hospital in Italy from December to April and 0.8% of them tested positive for SARS-CoV-2 (20).

While there is increasing evidence of the comorbid occurrence of strokes among patients with coronavirus infection, there is also substantial evidence that pre-existing cerebrovascular disease led to worse clinical outcomes (21, 22). A pooled analysis involving four studies has been performed by Agarwal et al. and has shown that a previous history of stroke increases the severity of SARS-CoV-2 disease by 2.5 times (21). The same trend was observed in another study concluding that cerebrovascular disease among SARS-CoV-2 patients increased the risk of poor outcome and mortality with a relative risk of 2.04 and 2.38, respectively (22).

The Immunological and Thrombotic Mechanisms

Preliminary evidence shows a pro-coagulatory state associated with COVID-19 infection and development of ischemic stroke (40). There is also evidence that COVID-19 patients admitted with neurological disease, including stroke, have a significantly higher incidence of in-hospital mortality, incident delirium, and higher disability than patients without COVID-19 (49).

Various theories have been proposed as the putative mechanism leading to the increased occurrence of stroke in patients with coronavirus infection. Schulman et al. describe thrombosis to be associated with over activation of the immunosystem and hypercoagulation of the blood through the body including in the brain (33). Another hypothesis proposed is the imbalance in the expression of ACE1/ACE2 as a result of the preferential affinity of the SARS-CoV-2 to ACE2 receptors causing a disproportionate increase in the ACE1/ACE2 balance which has pro-inflammatory and organ damaging effects (32). Thus this mini- review aimed to report on the incidence of stroke among patients with SARS, MERS, and SARS-CoV2- and to elucidate the role of immunological and hypercoagulable mechanisms in acute stroke patients with SARS-CoV, MERS-CoV, and SARS-CoV-2 infection and its pathogenesis.

Immunological Mechanisms

Various mechanisms have been postulated for the pathogenesis of stroke in patients with coronavirus infection. This includes triggering of the immunological pathways, which results in the activation of the macrophages by the granulocyte–macrophage colony-stimulating factor (GM-CSF) (33). This results in a cytokine surge with a concomitant release of large amounts of Interleukin-6 and other cytokines and chemokines such as interleukin (IL)-2, IL-7, interferon-γ inducible protein 10(IP-10, CXCL10), monocyte chemoattractant protein 1, macrophage inflammatory protein 1-α, and tumor necrosis factor-α (33, 36). These phenomena are reported to be responsible for the cytokine storm triggered by the hyperinflammatory state known to affect blood vessels and further cascade of negative effects in hemostasis leading to vasoconstriction and a prothrombotic state (36, 37). This is further supported by autopsy findings of endotheliitis in patients with SARS-CoV-2 (37). Another hypothesized mechanism is the development of allo-antibodies to ACE2, which also generate a delayed immune response which contributes further to the cytokine storm (34). This state also disrupts the body's physiological capacity to regulate inflammatory and hemostatic processes leading to prothrombotic, pro-inflammatory state and multi-organ damage (34, 50).

Disruption of the ACE1-ACE2 Balance

Direct attack and damage of the SARS-CoV-2 on the ACE2 receptors of the glial cells of the brain is another putative mechanism for the occurrence of cerebral thrombosis among infected patients (32). Normal activation of ACE-2 is known to be neuroprotective and counteracts the ill effects of the ACE1/angiotensin II/AT1 axis (32). Its depletion favors the activity of the latter, which may lead to a hyperinflammatory state and a cascade of damaging effects to target organs. Direct binding of the virus to the receptors on the endothelial cells may also impair blood pressure control mechanism and oxygen and glucose transfer to cells which may further induce neurological damage (35).

The Treatment Options and Outcome

Patients comorbid for coronavirus infection and stroke have usually been treated acutely with standard care regimens such as intravenous thrombolysis and endovascular clot retrieval (ECR) as per standard acute stroke guidelines. Three of the five stroke patients during the SARS-CoV pandemic were treated with intravenous immunolglobulin (IVIg). Three out of four MERS-CoV patients were treated with antibiotic and one with IVIg.

Other therapeutic options are currently being investigated including, recombinant ACE2, which may act primarily by competing with he SARS S protein and prevention of the depletion of the receptors (32). Humanized monoclonal antibodies such as tocilizumab and sarilumab, that block the Il-6 receptor have also shown potential in the treatment of vascular complications of human coronavirus (36).

Neurorehabilitation Challenges

The rapid spread of COVID-19 has become a pandemic emergency departments, choking emergency departments, infectious diseases, and intensive care units. Rehabilitation services have also become affected, causing radical changes both in the organization and in the operating methods (51). Major changes in structure and function of neurorehabilitation and rehabilitation activities during COVID-19 emergency are required, carefully balancing the provision of services useful to the patient and the reduction of the risk of spreading the virus. Stroke in patients with coronavirus infection confers poor clinical outcomes.

Discussion

Current figures indicate that stroke is not unusual in COVID patients and in fact incidence figures are likely to be a gross underestimation given the novelty of the virus and the fact that imaging is not often undertaken to ascertain cerebro-vascular events. Indeed, confirmatory brain imaging is unusual in COVID-19 patients as they usually require sedation and ventilation.

Eight thousand and ninety-eight cases of SARS infections were reported by WHO during the 2003 outbreak with 10% (774) mortality rate (48). Of these, five patients with an average age of 58 were further identified as suffering a stroke associated with SARS-CoV. Out of these five, three died for a 60% mortality. The high rate of thrombotic complications and the uniform pattern of large vessel ischemic strokes suggested a pro-coagulant state among patients infected with SARS-CoV (14).

While the confirmed cases of MERS-CoV were less than SARS-CoV with around 2,495 cases confirmed worldwide, the reported mortality rate was more than three times higher (585/35%). Three cases of stroke related MERS-CoV were reported. The average age was 54 years and mortality rate of 100% (i.e., 3 out of 3).

To date, COVID-19 has been associated with published cases of stroke among individuals with a mean age of around 65. A quarter of patients were younger than 65 years of age. Hypertension, diabetes, smoking, dyslipidemia are among the reported risk factors for stroke among these patients through in many of these patients a comprehensive stroke work up is not available.

Owing to the immunological nature of the disease, immunoglobulin supplementation has been used in three SARS CoV-1 patients with stroke (14). Currently, there is no published evidence of immunoglobulin use among MERS and SARS-CoV-2 patients. As of July 2020, the majority of COVID-19 patients who also experienced AIS in the US also showed high cerebrovascular risk factors (52). Furthermore, there is still a large gap in the literature regarding underlying mechanisms of stroke in human patients with coronavirus infection.

Preliminary reports (53) suggest that there are three predominant COVID-19- related mechanisms independent of risk factors. These include the hypercoagulable state, vasculitis, and cardiomyopathy (53). It has been postulated that the affinity of the SARS-CoV-2 for ACE2 receptors in the brain allows the virus to damage intracranial arteries, causing vessel wall rupture. Poyiadji et al. (54) suggesting that it is possible that the cytokine storm that accompanies the wall rupture might be the cause of hemorrhagic strokes. This was evident in a COVID-19 patient who developed an acute necrotizing encephalopathy associated with late parenchymal brain hemorrhages. Examining hospitalized patients with COVID-19.

Franceschi et al. (55) found that a combination of cytokine release syndrome and direct SARS-CoV-2–mediated breakdown of the blood–brain barrier may be responsible for hemorrhagic posterior reversible encephalopathy syndrome. In COVID-19 patients, there has also been secondary hemorrhagic transformation of ischemic strokes which may happen in the setting of endothelial damage or a consumption coagulopathy accompanying COVID-19 (53).

Further research is needed to elucidate the role or roles that the activation of the immunological and hypercoagulable pathways and specific risk factors potentially play in underlying susceptibility to coronavirus infection and associated stroke to facilitate the design of better treatment options in the future.

Currently, the total global data on stroke epidemiology during the COVID-19 pandemic is obviously not available. This review provides comprehensive but preliminary assimilation of anecdotal observations, case reports, single center experiences worldwide to date. Anecdotal reports have confirmed a reduction in single event stroke admissions to the hospitals during the global pandemic (47, 56) raising questions whether this is causing more collateral damage by keeping definite mild strokes at home and making these patients more vulnerable to post stroke depression, anxiety, poor quality of life? All these possibilities are hypothetical at present. Only well-designed, prospective research studies will be able to answer these speculations.

Implications for Recovery and Rehabilitation

As of this writing, there are almost 30 million global cases of COVID-19, with global deaths quickly approaching one million. Over 20 million people have recovered from the disease (57). However, there seems to be very little constructive evaluation of what recovery means in the context of a pandemic where the number of infections continues to increase daily, and a small number of cases of reinfection, possibly via a more recent mutated version of the virus are beginning to appear. Among those reported in the press as no longer hospitalized, there is also a growing number who claim that although home they are far from fully recovered with ongoing problems of fatigue, continuing chest and breathing difficulties and mental health issues (58). What rehabilitation is available to such dehospitalized patients remains to be rigorously investigated.

Lastly, the nature of the virus means that until an effective generalized vaccine exists, the protocols of rehabilitation must change. Social distancing, masks, and telehealth format mean alternate devices for remote continuous physiological monitoring of a patients' health must be made available and incorporated into design of management regimes. In particular, measures of activity, oximetry, heart rate variability, and blood pressure for monitoring of oxygen availability and cardiac output are required during exercise routines and as physiological measures of sleep efficiency that act as surrogate measures of mental health (59).

Limitations of This Review

This review has been limited to publications in the English language. Most of the publications describe the experience in managing acute stroke patients with SARS-CoV-2, as the far smaller numbers associated with MERS and SARS-CoV necessarily meant there were less comorbid examples of SARS and stroke and hence predominantly case studies. Furthermore, in most cases only patients with ischemic stroke were extensively reviewed, possibly because patients with hemorrhagic strokes died early.

Conclusion

Patients with COVID-19 exhibit a higher risk of acute ischemic stroke compared with patients with other respiratory tract infections. It is important that medical staff are cognizant of potential neurological complications when treating COVID-19. Health personnel engaged in acute stroke care are at risk of acquiring COVID-19 infection from stroke patients with COVID-19 infection.

There is an increased number of reported strokes during the current COVID-19 pandemic with far greater incidence and apparent contagion rates. Patients with COVID-19 exhibit a higher risk of acute ischemic stroke compared with patients with other respiratory tract infections. In terms of COVID-19 and stroke, greater incidence has been seen in the young where most strokes are associated with large vessel occlusion, and most patients have no previous history of stroke or traditional stroke risk factors. The immunologic and hypercoagulable nature of the disease is displayed by the disproportionate rise in the laboratory markers such as D-dimer, CRP, and ferritin. Standard of care treatment with systemic thrombolysis and endovascular retrieval and therapeutic anticoagulation is being used as the standard treatment at present. However it is beyond the scope of this review to address this aspect in-depth as the COVID-19 pandemic is still unfolding. It is likely that anticoagulation will play an important role in the management of stroke in COVID-19.

As more recovering COVID-19 patients are transferred to rehabilitation services and support, there is a strong need for UpToDate clinician knowledge of increased thrombo-embolic risk in this population. Clinicians need to educate patients about thrombotic events associated with COVID-19 infection. There is also a need to use neuroimaging in the post-acute setting for COVID-19 patients given the prevalence of neurological findings. As bed availability is at a premium and outpatient facilities limited due to the pandemic, access to effective rehabilitation will become challenging.

Another problem for healthcare providers engaged in acute stroke care is the risk of acquiring COVID-19 infection from infected stroke patients. As the best strategy to avoid transmission involves not being in the same space with suspected or confirmed COVID-19 stroke patient, providers should maximize the use of Telestroke or a commercially available low-cost smartphone application system to perform all aspects of acute stroke evaluation.

Author Contributions

TW, LK, and SC conceived of the presented idea. LK developed the idea further and performed the literature search and drafted the manuscript. CS and TW conducted independent literature search and contributed the PRISMA chart as a group. TW, SC, and CS made significant contributions to the manuscript. All authors approved the final manuscript.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Wertheim JO, Chu DK, Peiris JS, Kosakovsky Pond SL, Poon LL. A case for the ancient origin of coronaviruses. J Virol. 87:7039–45. doi: 10.1128/JVI.03273-12

CrossRef Full Text | Google Scholar

2. Cui J, Li F, Shi Z. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. (2018) 17:181–92. doi: 10.1038/s41579-018-0118-9

PubMed Abstract | CrossRef Full Text | Google Scholar

3. Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. Virol J. (2019) 16:69. doi: 10.1186/s12985-019-1182-0

PubMed Abstract | CrossRef Full Text | Google Scholar

4. Bridwell R, Long B, Gottlieb M. Neurologic complications of COVID-19. Am J Emergency Med. (2020) 38:e1543–9.e1547. doi: 10.1016/j.ajem.2020.05.024

PubMed Abstract | CrossRef Full Text | Google Scholar

5. Woo P, Lau S, Lam C, Lau C, Tsang A, Lau J, et al. Discovery of seven novel mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus. J Virol. (2012) 86:3995–4008. doi: 10.1128/JVI.06540-11

PubMed Abstract | CrossRef Full Text | Google Scholar

6. Hui K, Cheung M, Perera R, Ng K, Bui C, Ho J, et al. Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures. Lancet Respir Med. (2020) 8:687–95. doi: 10.1016/S2213-2600(20)30193-4

PubMed Abstract | CrossRef Full Text | Google Scholar

7. Mao R, Qiu Y, He J, Tan J, Li X, Liang J, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. (2020) 5:667–78. doi: 10.1016/S2468-1253(20)30126-6

PubMed Abstract | CrossRef Full Text | Google Scholar

8. Oudit GY, Kassiri Z, Jiang C, Liu PP, Poutanen SM, Penninger JM, et al. SARS-coronavirus modulation of myocardial ACE2 expression inflammation in patients with SARS. Eur J Clin Invest. (2009) 39:618–25. doi: 10.1111/j.1365-2362.2009.02153.x

PubMed Abstract | CrossRef Full Text | Google Scholar

9. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. (2020) 77:683–90. doi: 10.1001/jamaneurol.2020.1127

PubMed Abstract | CrossRef Full Text | Google Scholar

10. Tsai L, Hsieh S, Chao C, Chen Y, Lin Y, Chang S, et al. Neuromuscular disorders in severe acute respiratory syndrome. Arch Neurol. (2004) 61:1669. doi: 10.1001/archneur.61.11.1669

CrossRef Full Text | Google Scholar

11. Kim J, Heo J, Kim H, Song S, Park S, Park T, et al. Neurological complications during treatment of middle east respiratory syndrome. J Clin Neurol. (2017) 13:227. doi: 10.3988/jcn.2017.13.3.227

PubMed Abstract | CrossRef Full Text

12. Avula A, Nalleballe K, Narula N, Sapozhnikov S, Dandu V, Toom S, et al. COVID-19 presenting as stroke. Brain Behav Immun. (2020) 87:115–9. doi: 10.1016/j.bbi.2020.04.077

PubMed Abstract | CrossRef Full Text | Google Scholar

13. Arksey H, O'Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. (2005) 8:19–32. doi: 10.1080/1364557032000119616

CrossRef Full Text | Google Scholar

14. Umapathi T, Kor AC, Venketasubramanian N, Lim CC, Pang BC, Yeo TT, et al. Large artery ischaemic stroke in severe acute respiratory syndrome (SARS). J Neurol. (2004) 251:1227–31. doi: 10.1007/s00415-004-0519-8

PubMed Abstract | CrossRef Full Text | Google Scholar

15. Arabi YM, Harthi A, Hussein J, Bouchama A, Johani S, Hajeer AH, et al. Severe neurologic syndrome associated with Middle East respiratory syndrome corona virus (MERS-CoV). Infection. (2015) 43:495–501. doi: 10.1007/s15010-015-0720-y

PubMed Abstract | CrossRef Full Text | Google Scholar

16. Al-Hameed FM. Spontaneous intracranial hemorrhage in a patient with middle east respiratory syndrome corona virus. Saudi Med J. (2017) 38:196–200. doi: 10.15537/smj.2017.2.16255

PubMed Abstract | CrossRef Full Text | Google Scholar

17. Algahtani H, Subahi A, Shirah B. Neurological complications of middle east respiratory syndrome coronavirus: a report of two cases and review of the literature. Case Rep Neurol Med. (2016) 2016:1–6. doi: 10.1155/2016/3502683

PubMed Abstract | CrossRef Full Text | Google Scholar

18. Lodigiani C, Japichino G, Carenzo L, Cecconi M, Ferrazzi P, Sebastian T, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thrombosis Res. (2020) 191:9–14. doi: 10.1016/j.thromres.2020.04.024

PubMed Abstract | CrossRef Full Text | Google Scholar

19. Klok F, Kruip M, van der Meer N, Arbous M, Gommers D, Kant K, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thrombosis Res. (2020) 191:148–50. doi: 10.1016/j.thromres.2020.04.041

PubMed Abstract | CrossRef Full Text | Google Scholar

20. Tejada Meza H, Lambea Gil Á, Sancho Saldaña A, Villar Yus C, Pardiñas Barón B, Sagarra Mur D, et al. Ischaemic stroke in the time of coronavirus disease 2019. Eur J Neurol. (2020) 2019:1788–92. doi: 10.1111/ene.14327

PubMed Abstract | CrossRef Full Text | Google Scholar

21. Aggarwal G, Lippi G, Michael Henry B. Cerebrovascular disease is associated with an increased disease severity in patients with coronavirus disease 2019 (COVID-19): a pooled analysis of published literature. Int J Stroke. (2020) 15:385–9. doi: 10.1177/1747493020921664

PubMed Abstract | CrossRef Full Text | Google Scholar

22. Pranata R, Huang I, Lim M, Wahjoepramono P, July J. Impact of cerebrovascular and cardiovascular diseases on mortality and severity of COVID-19 – systematic review, meta-analysis, and meta-regression. J Stroke Cerebrovasc Dis. (2020) 29:104949. doi: 10.1016/j.jstrokecerebrovasdis.2020.104949

CrossRef Full Text | Google Scholar

23. Viguier A, Delamarre L, Duplantier J, Olivot J, Bonneville F. Acute ischemic stroke complicating common carotid artery thrombosis during a severe COVID-19 infection. J Neuroradiol. (2020) 47:393–4. doi: 10.1016/j.neurad.2020.04.003

PubMed Abstract | CrossRef Full Text | Google Scholar

24. Tunç A, Ünlübaş Y, Alemdar M, Akyüz E. Coexistence of COVID-19 and acute ischemic stroke report of four cases. J Clin Neurosci. (2020) 7:227–9. doi: 10.1016/j.jocn.2020.05.018

PubMed Abstract | CrossRef Full Text | Google Scholar

25. Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoirah H, Singh IP, et al. Large-Vessel stroke as a presenting feature of covid-19 in the young. N Engl J Med. (2020) 382:e60. doi: 10.1056/NEJMc2009787

PubMed Abstract | CrossRef Full Text | Google Scholar

26. Valderrama E, Humbert K, Lord A, Frontera J, Yaghi S. Severe acute respiratory syndrome coronavirus 2 infection and ischemic stroke. Stroke. (2020) 51:e124–7. doi: 10.1161/STROKEAHA.120.030153

PubMed Abstract | CrossRef Full Text | Google Scholar

27. Beyrouti R, Adams M, Benjamin L, Cohen H, Farmer S, Goh Y, et al. Characteristics of ischaemic stroke associated with COVID-19. J Neurol Neurosurg Psychiatry. (2020) 91:889–91. doi: 10.1136/jnnp-2020-323586

PubMed Abstract | CrossRef Full Text | Google Scholar

28. Berekashvili K, Dmytriw A, Vulkanov V, Agarwal S, Khaneja A, Turkel-Parella D, et al. Etiologic subtypes of ischemic stroke in SARS-COV-2 Virus patients. Front Neurol. (2020) 11:1004. doi: 10.3389/fneur.2020.01004

PubMed Abstract | CrossRef Full Text | Google Scholar

29. Moshayedi P, Ryan T, Mejia L, Nour M, Liebeskind D. Triage of acute ischemic stroke in confirmed covid-19: large vessel occlusion associated with coronavirus infection. Front Neurol. (2020) 11:353. doi: 10.3389/fneur.2020.00353

PubMed Abstract | CrossRef Full Text | Google Scholar

30. Co C, Yu J, Laxamana L, David-Ona D. Intravenous thrombolysis for stroke in a covid-19 positive filipino patient, a case report. J Clin Neurosci. (2020) 77:234–6. doi: 10.1016/j.jocn.2020.05.006

PubMed Abstract | CrossRef Full Text | Google Scholar

31. Deliwala S, Abdulhamid S, Abusalih M, Al-Qasmi M, Bachuwa G. Encephalopathy as the sentinel sign of a cortical stroke in a patient infected with coronavirus disease-19 (COVID-19). Cureus. (2020) 12:e8121. doi: 10.7759/cureus.8121

PubMed Abstract | CrossRef Full Text | Google Scholar

32. Hess D, Eldahshan W, Rutkowski E. COVID-19-Related Stroke. Transl Stroke Res. (2020) 11:322–5. doi: 10.1007/s12975-020-00818-9

PubMed Abstract | CrossRef Full Text | Google Scholar

33. Schulman S. Coronavirus Disease 2019. Prothrombotic factors, and venous thromboembolism. Semin Thromb Hemost. (2020) 46:772–6. doi: 10.1055/s-0040-1710337

PubMed Abstract | CrossRef Full Text | Google Scholar

34. Amiral J, Vissac A, Seghatchian J. Covid-19, induced activation of hemostasis, and immune reactions: can an auto-immune reaction contribute to the delayed severe complications observed in some patients? Transf Apheresis Sci. (2020) 59:102804. doi: 10.1016/j.transci.2020.102804

PubMed Abstract | CrossRef Full Text | Google Scholar

35. Calcagno N, Colombo E, Maranzano A, Pasquini J, Keller Sarmiento I, Trogu F, et al. Rising evidence for neurological involvement in COVID-19 pandemic. Neurol Sci. (2020) 41:1339–41. doi: 10.1007/s10072-020-04447-w

PubMed Abstract | CrossRef Full Text | Google Scholar

36. Debuc B, Smadja D. Is COVID-19 a new hematologic disease? Stem Cell Rev Rep. (2020) 12:1–5. doi: 10.1007/s12015-020-09987-4

PubMed Abstract | CrossRef Full Text | Google Scholar

37. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. (2020) 395:1417–8. doi: 10.1016/S0140-6736(20)30937-5

PubMed Abstract | CrossRef Full Text | Google Scholar

38. Escalard S, Maïer B, Redjem H, Delvoye F, Hébert S, Smajda S, et al. Treatment of acute ischemic stroke due to large vessel occlusion with COVID-19: experience from Paris. Stroke. (2020) 51:2540–3. doi: 10.1161/STROKEAHA.120.030574

PubMed Abstract | CrossRef Full Text

39. Zubair AS, McAlpine LS, Gardin T, Farhadian S, Kuruvilla DE, Spudich S. Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: a review. JAMA Neurol. (2020) 77:1018–27. doi: 10.1001/jamaneurol.2020.2065

PubMed Abstract | CrossRef Full Text | Google Scholar

40. Benussi A, Pilotto A, Premi E, Libri I, Giunta M, Agosti C, et al. Clinical characteristics and outcomes of inpatients with neurologic disease and COVID-19 in Brescia, Lombardy, Italy. Neurology. (2020) 95:e910–20. doi: 10.1212/WNL.0000000000009848

PubMed Abstract | CrossRef Full Text | Google Scholar

41. Markus H, Brainin M. COVID-19 and stroke—a global world stroke organization perspective. Int J Stroke. (2020) 15:361–4. doi: 10.1177/1747493020923472

PubMed Abstract | CrossRef Full Text | Google Scholar

42. Filatov A, Sharma P, Hindi F, Espinosa PS. Neurological complications of coronavirus disease (covid-19): encephalopathy. Cureus. (2020) 12:e7352. doi: 10.7759/cureus.7352

CrossRef Full Text | Google Scholar

43. Orsucci D, Ienco EC, Nocita G, Napolitano A, Vista M. Neurological features of COVID-19 and their treatment: a review. Drugs Context. (2020) 9:2020-5-1. doi: 10.7573/dic.2020-5-1

PubMed Abstract | CrossRef Full Text | Google Scholar

44. Ahmada I, Rathoreb FA. Neurological manifestations and complications of COVID-19: A literature review. J Clin Neurosci. (2020) 77:8–12. doi: 10.1016/j.jocn.2020.05.017

PubMed Abstract | CrossRef Full Text | Google Scholar

45. Sharifian-Dorche M, Huot P, Osherov M, Wen D, Saveriano A, Giacomini PS, et al. Neurological complications of coronavirus infection; a comparative review and lessons learned during the COVID-19 pandemic. J Neurol Sci. (2020) 417:117085. doi: 10.1016/j.jns.2020.117085

PubMed Abstract | CrossRef Full Text | Google Scholar

46. Sellner J, Taba P, Öztürk S, Helbok R. The need for neurologists in the care of COVID-19 patients. Eur J Neurol. (2020) 27:e31–2. doi: 10.1111/ene.14257

PubMed Abstract | CrossRef Full Text | Google Scholar

47. Morelli N, Rota E, Terracciano C, Immovilli P, Spallazzi M, Colombi D, et al. The baffling case of ischemic stroke disappearance from the casualty department in the covid-19 era. Eur Neurol. (2020) 83:213–5. doi: 10.1159/000507666

PubMed Abstract | CrossRef Full Text | Google Scholar

48. World Health Organisation (WHO). Middle East Respiratory Syndrome Coronavirus (MERS-CoV)—Update. Available online at: https://www.who.int/emergencies/mers-cov/en/

Google Scholar

49. Bartolo M, Intiso D, Lentino C, Sandrini G, Paolucci S, Zampolini M, et al. Urgent measures for the containment of the coronavirus (covid-19) epidemic in the neurorehabilitation/rehabilitation departments in the phase of maximum expansion of the epidemic. Front. Neurol. (2020) 11:423. doi: 10.3389/fneur.2020.00423

PubMed Abstract | CrossRef Full Text | Google Scholar

50. Zhang L, Yan X, Fan Q, Liu H, Liu X, Liu Z, et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost. (2020) 18:1324–9. doi: 10.1111/jth.14859

PubMed Abstract | CrossRef Full Text | Google Scholar

51. Rothstein A, Oldridge O, Schwennesen H, Do D, Cucchiara BL. Acute cerebrovascular events in hospitalized covid-19 patients. Stroke. (2020) 51:e219–22. doi: 10.1161/STROKEAHA.120.030995

PubMed Abstract | CrossRef Full Text | Google Scholar

52. Spence JD, de Freitas GR, Pettigrew LC, Ay H, Liebeskind DS, Kase CS, et al. Mechanisms of Stroke in COVID-19. Cerebrovasc Dis. (2020) 49:451–8. doi: 10.1159/000509581

PubMed Abstract | CrossRef Full Text | Google Scholar

53. John Hopkins institute. Available online at: https://coronavirus.jhu.edu

54. Poyiadji N, Shahin G, Noujaim D, Stone M, Patel S, Griffith B. COVID-19-associated acute hemorrhagic necrotizing encephalopathy: imaging features. Radiology. (2020) 296:E119–E120. doi: 10.1148/radiol.2020201187

PubMed Abstract | CrossRef Full Text

55. Franceschi AM, Ahmed O, Giliberto L, Castillo M. Hemorrhagic posterior reversible encephalopathy syndrome as a manifestation of COVID-19 infection. Am J Neuroradiol. (2020) 41:1173–6. doi: 10.3174/ajnr.A6595

PubMed Abstract | CrossRef Full Text | Google Scholar

56. Sandercock P. Full heparin anticoagulation should not be used in acute ischemic stroke. Stroke. (2003) 34:231–2. doi: 10.1161/01.STR.0000047037.38062.24

PubMed Abstract | CrossRef Full Text | Google Scholar

57. Soy M, Keser G, Atagündüz P, Tabak F, Atagündüz I, Kayhan S. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clin Rheumatol. (2020) 39:2085–94. doi: 10.1007/s10067-020-05190-5

PubMed Abstract | CrossRef Full Text | Google Scholar

58. Baroutjian A, Sanchez C, Boneva D, McKenney M, Elkbuli A. SARS-CoV-2 pharmacologic therapies and their safety/effectiveness according to level of evidence. Am J Emergency Med. (2020) 38:2405–15. doi: 10.1016/j.ajem.2020.08.091

PubMed Abstract | CrossRef Full Text | Google Scholar

59. Ellul MA, Benjamin L, Singh B, Lant S, Michael BD, Easton A, et al. Neurological associations of COVID-19. Lancet Neurol. (2020) 19:767–83. doi: 10.1016/S1474-4422(20)30221-0

CrossRef Full Text | Google Scholar

Keywords: COVID-19, hypercoaguability, ACE—angiotensin-converting enzyme, rehabilitation, SARS, MERS, SARS-CoV2, inflammation

Citation: Karimi L, Sales C, Crewther SG and Wijeratne T (2020) Acute Ischemic Stroke in SARS-CoV, MERS-CoV, SARS-CoV-2: Neurorehabilitation Implications of Inflammation Induced Immunological Responses Affecting Vascular Systems. Front. Neurol. 11:565665. doi: 10.3389/fneur.2020.565665

Received: 25 May 2020; Accepted: 05 October 2020;
Published: 22 December 2020.

Edited by:

Thomas Platz, University of Greifswald, Germany

Reviewed by:

Keith M. McGregor, Emory University, United States
Marco Paoloni, Sapienza University of Rome, Italy

Copyright © 2020 Karimi, Sales, Crewther and Wijeratne. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Tissa Wijeratne, tissa.wijeratne@wh.org.au